ABSTRACT
Lomentospora prolificans is a filamentous fungus and an emerging pathogen in immunocompromised patients. It is encountered most commonly in Australia, Spain, and USA. We described the first case of Lomentospora prolificans fungemia in South America. The patient was a hematopoietic stem cell transplantation (HSCT) recipient who developed the infection 37 days after stem cells infusion. In addition, we performed a literature review of invasive lomentosporiosis in HSCT patients.
Subject(s)
Fungemia/microbiology , Hematopoietic Stem Cell Transplantation/adverse effects , Immunocompromised Host , Scedosporium/pathogenicity , Transplantation Conditioning/adverse effects , Adolescent , Antifungal Agents/therapeutic use , Cord Blood Stem Cell Transplantation/adverse effects , Cord Blood Stem Cell Transplantation/methods , DNA, Fungal/isolation & purification , Fungemia/diagnostic imaging , Fungemia/drug therapy , Fungemia/immunology , Granulomatous Disease, Chronic/surgery , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Radiography , Scedosporium/genetics , Scedosporium/isolation & purification , South America , Transplantation Conditioning/methodsSubject(s)
Cognitive Dysfunction , Granulomatous Disease, Chronic/diagnosis , Mastitis/diagnosis , Breast Neoplasms/diagnosis , Breast Neoplasms/diagnostic imaging , Diagnosis, Differential , Female , Granulomatous Disease, Chronic/diagnostic imaging , Granulomatous Disease, Chronic/surgery , Humans , Mastitis/diagnostic imaging , Mastitis/surgery , Middle AgedSubject(s)
Fever/diagnosis , Granulomatous Disease, Chronic/diagnosis , Thoracic Wall/surgery , Edema/etiology , Edema/therapy , Emergencies , Fever/therapy , Granulomatous Disease, Chronic/surgery , Granulomatous Disease, Chronic/therapy , Humans , Infant , Leukocytes/metabolism , Leukocytes/pathology , Male , Radiography , Shock/etiology , Shock/therapy , Thoracic Wall/diagnostic imaging , Thoracic Wall/pathology , Thoracotomy , Treatment OutcomeABSTRACT
In a retrospective study, the effect of long-term treatment with sulfamethoxazole-trimethoprim was evaluated in nine male patients with chronic granulomatous disease. During this treatment, a marked reduction was observed in the number of infectious episodes, the number of causative agents, and the number of surgical interventions. Furthermore, a significant reduction in days of hospitalization per year was found. The mean observation period was six years before and four years during treatment. Transient alopecia was observed in one patient during therapy. We conclude that prophylactic treatment with sulfamethoxazole-trimethoprim is beneficial in patients with chronic granulomatous disease.